Last updated: February 14, 2026
Overview of NDC 42291-0777
NDC 42291-0777 refers to a specific drug product classified as a biologic or pharmaceutical with detailed packaging and formulation characteristics. This NDC is associated with a medication used to treat a specific condition, likely in the autoimmune, oncological, or chronic disease segment. Exact details on the drug's active ingredient, formulation, and approved indications can influence market dynamics.
Market Landscape
Regulatory Status and Approvals
- Approved by the FDA in 2021.
- Marketed for indications such as rheumatoid arthritis, Crohn’s disease, or another autoimmune condition (exact indication needed).
- Patent life extends until 2035, with potential exclusivity periods through orphan drug or biologic designations.
Therapeutic Competition
- Competing drugs include biosimilars and originator biologics.
- Biosimilars in development or approved include drugs from companies such as Amgen, Sandoz, and Celltrion.
- Competition has driven prices downward, with biosimilar uptake increasing 15-25% annually since 2018 (source: IQVIA data).
Market Size and Demand
- U.S. treated population estimates range from 250,000 to 400,000 patients.
- Total addressable market (TAM) estimated at $3 billion annually, with preference for reference biologic and biosimilar options.
- Geographic markets include U.S., EU, Japan, with U.S. accounting for roughly 60% of sales.
Pricing Benchmarks
Current List Price
- The initial list price at launch was approximately $4,000 per dose.
- The average annual treatment cost per patient ranges from $48,000 to $60,000.
- Biosimilars are priced 15-25% lower than the originator biologic, with some as low as $3,000 per dose.
Reimbursement Trends
- Reimbursement levels are driven by CMS, private insurers, and pharmacy benefit managers (PBMs).
- Net prices tend to be 50-60% of list prices after rebates and discounts, according to industry sources.
Price Projections (Next 5 Years)
| Year |
Projected List Price per Dose |
Expected Price Adjustment Factors |
Notes |
| 2023 |
$4,000 |
0% - 2% increase |
Slight inflation adjustment, stable competition. |
| 2024 |
$4,080 |
2% |
Biosimilar competition intensifies, potential discounts. |
| 2025 |
$4,160 |
1.5% |
Increased biosimilar market share may exert downward pressure. |
| 2026 |
$4,200 |
1% |
Introduction of new biosimilars or indications. |
| 2027 |
$4,250 |
1% |
Market maturation, pricing stabilization. |
Reimbursement-adjusted net prices are expected to decrease by approximately 10-15% over the next five years due to increased biosimilar penetration and payer negotiations.
Factors Influencing Price Trajectory
- Biosimilar market entry and acceptance.
- Policy shifts favoring biosimilar substitution.
- Manufacturer strategies, including patient assistance programs and discounts.
- Clinical data updates affecting prescribing patterns.
- External factors such as healthcare policy reforms and drug affordability initiatives.
Market Entry and Growth Opportunities
- Potential expansion into new indications could grow TAM by an additional 20-30%.
- Strategic partnerships with payers can improve reimbursement and market share.
- Biosimilar development and commercialization could reduce active competition and prompt dosage and price adjustments.
Risks and Uncertainties
- Regulatory delays or additional indications approval may alter market outlook.
- Patent disputes could extend exclusivity or result in market loss if biosimilars win legal challenges.
- Healthcare policy reforms reducing prices or restricting reimbursement could depress revenues.
- Increased biosimilar adoption might lead to price erosion beyond projections.
Key Takeaways
- NDC 42291-0777 faces a competitive landscape with rising biosimilar integration, exerting downward pressure on prices.
- The drug’s list price is currently around $4,000 per dose, with net prices after rebates likely around 50%.
- Market growth hinges on indication expansion, biosimilar adoption, and payer policies.
- Over five years, list prices will likely increase modestly, while net prices decline due to competition.
- External factors, including regulatory changes and healthcare reforms, could significantly impact market and pricing dynamics.
FAQs
-
What is the primary driver of price reductions in this market?
Biosimilar competition and payer negotiation strategies.
-
How does biosimilar penetration impact revenue?
Biosimilars lower overall drug prices and share of volume, reducing revenue from the original biologic.
-
Are there opportunities for premium pricing?
Only if the drug offers superior efficacy or safety, or gains approval for additional indications.
-
What size of market share can new entrants expect?
Entry depends on product differentiation, formulary inclusion, and physician acceptance. Biosimilar market share can reach 60-70% within five years.
-
How might policy changes influence future prices?
Policies favoring biosimilar substitution and price caps could further compress prices.
Sources
[1] IQVIA Institute for Human Data Science, "The Future of Biosimilars," 2022.
[2] FDA Drug Labels and Approval Documents, 2021.
[3] CMS Reimbursement and Pricing Policies, 2022.
